查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1700104

2032 年SEVOFLURANE市場預測：按產品、配方、分銷管道、應用、最終用戶和地區進行的全球分析

Sevoflurane Market Forecasts to 2032 - Global Analysis by Product (Generic Sevoflurane and Branded Sevoflurane), Formulation, Distribution Channel, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球SEVOFLURANE市場預計在 2025 年達到 4.761 億美元，到 2032 年將達到 7.399 億美元，預測期內的複合年成長率為 6.5%。

SEVOFLURANE是一種揮發性吸入麻醉劑，廣泛用於全身麻醉的誘導和維持。它是一種無色、不易燃的液體，具有甜味，非常適合兒科和成人患者使用。SEVOFLURANE以其快速的麻醉起效和恢復而聞名，它可以最大限度地減少呼吸道刺激並實現平穩的麻醉誘導。較低的血氣分配係數可以快速調整麻醉深度。它通常耐受性良好，但可能導致劑量相關性低血壓，並且罕見地導致腎毒性。

根據2021年出版的《世界外科雜誌》報道，印度進行了3,646例手術，以滿足民眾的手術需求。

增加外科手術

全球外科手術數量的增加推動了SEVOFLURANE市場的顯著成長。SEVOFLURANE是一種常用的吸入麻醉劑，因其誘導和恢復時間快，在醫院和門診手術中心使用。由於慢性病發病率上升、微創手術的改進以及更大規模醫療保健系統的發展，需求也在成長。由於人口老化導致外科手術需求增加，SEVOFLURANE在現代麻醉實踐中的重要作用得到了不斷擴大的市場的進一步支持。

與其他方案相比高成本

與其他麻醉劑相比，SEVOFLURANE的高成本是市場成長的主要障礙。醫療機構，尤其是在成本敏感地區的醫療機構，可能會選擇Isoflurane或DESFLURANE等成本較低的替代品，從而限制SEVOFLURANE的採用。這種成本障礙將影響採購決策，尤其是在新興市場，進而降低整體需求。此外，SEVOFLURANE的使用可能會在對價格敏感的醫院和診所受到限制，從而影響製造商的銷售和收益成長。

麻醉技術的進展

麻醉技術的進步提高了患者的安全性、準確性和手術效率，從而推動了市場的顯著成長。自動麻醉輸送、即時監控和低流量技術等創新最佳化了SEVOFLURANE的使用，減少了浪費和副作用。微創手術的興起和汽化器的改進進一步推動了需求。此外，改善的藥物動力學和恢復情況使SEVOFLURANE成為麻醉師的首選。總的來說，這些進步正在推動市場擴張，使全球麻醉服務更加安全、有效。

潛在的副作用

SEVOFLURANE市場面臨監管限制、供應鏈中斷和健康問題的潛在負面影響。有關揮發性麻醉劑的嚴格環境法規阻礙了市場擴張。供應鏈不穩定，包括原料短缺，將影響生產和定價。此外，對兒童和老年人神經毒性的擔憂引發了安全問題，導致採用率低。來自替代麻醉劑的競爭日益激烈以及對全身靜脈麻醉 (TIVA) 的日益偏好進一步限制了市場的成長和盈利。

COVID-19的影響：

COVID-19 疫情對SEVOFLURANE市場產生了各種影響。雖然封鎖導致擇期手術減少，但重症患者（尤其是新冠肺炎患者）的機械通氣對SEVOFLURANE的需求卻大幅增加。雖然供應鏈中斷和醫院資源重新分配最初減緩了市場成長，但疫情後的復甦、外科手術的增加以及醫療基礎設施的改善正在推動整個行業需求的強勁復甦。

預計預測期內醫院部門將實現最大幅度成長。

預計醫院部門將在預測期內佔據最大的市場佔有率，因為醫院是外科手術麻醉劑的主要使用者。手術量的增加、醫療基礎設施的改善以及麻醉技術的進步正在推動醫院對SEVOFLURANE的需求。此外，需要手術介入的慢性病的盛行率不斷上升也推動了市場的成長。由於其功效、安全性和在全身麻醉中的廣泛應用，該領域得到了廣泛的應用，增強了對市場擴張的正面影響。

預計高純度SEVOFLURANE市場在預測期內的複合年成長率最高

在預測期內，高純度SEVOFLURANE部分預計將呈現最高的成長率，因為它在麻醉應用中具有卓越的功效、安全性和減少的副作用。隨著外科手術的增加和對微創治療的需求不斷成長，醫院和診所優先考慮高純度配方以改善患者的治療效果。此外，嚴格的監管標準和藥品製造的進步確保了始終如一的質量，進一步促進了市場採用。

占比最大的地區

在預測期內，由於外科手術的增加、麻醉劑的技術發展以及醫療保健支出的增加，預計北美將佔據最大的市場佔有率。SEVOFLURANE因其有效性、恢復時間短、副作用少而被推薦為吸入性麻醉劑。人口老化和慢性病的增加也在推動需求。麻醉劑輸送技術的持續研究和開發進一步推動了它的普及。市場擴張正在刺激該地區尖端醫療保健基礎設施的發展，確保患者獲得更好的治療結果。

複合年成長率最高的地區：

預計亞太地區在預測期內的複合年成長率最高。這是由於外科手術的增加、醫療保健基礎設施的成長以及麻醉劑技術的突破。透過提供更安全、更有效的吸入麻醉劑，市場正在改善患者的治療效果。人口老化、醫療旅遊成長和醫院發展進一步推動了需求。SEVOFLURANE對於提高外科手術效果和一般醫療保健標準起著重要作用，而政府改善醫療保健機會的計劃也支持了市場成長。

免費客製化服務

訂閱此報告的客戶可享有以下免費自訂選項之一：

  • 公司簡介
    • 對其他市場公司（最多 3 家公司）進行全面分析
    • 主要企業的SWOT分析（最多3家公司）
  • 地理細分
    • 根據客戶興趣對主要國家市場進行估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 研究範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究材料
    • 主要研究資料
    • 次級研究資訊來源
    • 先決條件

第3章市場走勢分析

  • 驅動程式
  • 限制因素
  • 機會
  • 威脅
  • 產品分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • COVID-19的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買家的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

第5章 全球SEVOFLURANE市場（按產品）

  • 非專利SEVOFLURANE
  • 品牌SEVOFLURANE

第6章 全球SEVOFLURANE市場（依配方）

  • 標準純度SEVOFLURANE
  • 高純度SEVOFLURANE

第7章 全球SEVOFLURANE市場（依分銷管道）

  • 直銷
  • 分銷商/批發商
  • 網路藥局
  • 零售藥局

第8章 全球SEVOFLURANE市場（依應用）

  • 麻醉誘導
  • 麻醉維持

第9章 全球SEVOFLURANE市場（依最終用戶）

  • 醫院
  • 門診手術中心（ASC）
  • 專科診所
  • 其他醫療機構

第 10 章全球SEVOFLURANE市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第11章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第12章 公司概況

  • AbbVie Inc.
  • Accord Healthcare
  • AstraZeneca
  • Baxter International Inc.
  • Beijing Zizhu Pharmaceutical Co., Ltd.
  • Endo International plc
  • Fresenius Kabi AG
  • Hikma Pharmaceuticals PLC
  • Hospira Inc.
  • Jiangsu Hengrui Pharmaceuticals Co., Ltd.
  • Lunan Pharmaceutical Group Co., Ltd.
  • Maruishi Pharmaceutical Co., Ltd.
  • Merck KGaA
  • Piramal Critical Care
  • Shandong Keyuan Pharmaceutical Co., Ltd.
  • Shanghai Huayuan Ethylene Co., Ltd.
  • Troikaa Pharmaceuticals Ltd. .
Product Code: SMRC29007

According to Stratistics MRC, the Global Sevoflurane Market is accounted for $476.1 million in 2025 and is expected to reach $739.9 million by 2032 growing at a CAGR of 6.5% during the forecast period. Sevoflurane is a volatile, inhalational anesthetic widely used for inducing and maintaining general anesthesia. It is a colorless, non-flammable liquid with a sweet odor, making it ideal for pediatric and adult patients. Known for its rapid onset and recovery, sevoflurane provides smooth induction with minimal airway irritation. It has a low blood-gas partition coefficient, allowing quick adjustments in anesthesia depth. While generally well-tolerated, it can cause dose-dependent hypotension and rare nephrotoxicity.

According to the World Journal of Surgery published in 2021, 3646 operations were conducted to satisfy the surgical requirements of the population in India.

Market Dynamics:

Driver:

Increasing Surgical Procedures

The growing number of surgical procedures worldwide is propelling considerable growth in the sevoflurane market. Sevoflurane is a popular inhalation anesthetic that is used in hospitals and ambulatory surgery centers due to its quick induction and recovery times. Demand is also being increased by the growing incidence of chronic illnesses, improvements in less invasive surgery, and the development of a larger healthcare system. Sevoflurane's vital function in contemporary anesthetic methods is further supported by the market's expansion due to the aging population's increased need for surgical procedures.

Restraint:

High Cost Compared to Alternatives

The high cost of sevoflurane compared to alternative anesthetics significantly hinders its market growth. Healthcare facilities, especially in cost-sensitive regions, may opt for lower-cost substitutes like isoflurane or desflurane, limiting sevoflurane adoption. This cost barrier affects procurement decisions, particularly in developing markets, reducing its overall demand. Additionally, price-conscious hospitals and clinics may restrict its usage, impacting sales and revenue growth for manufacturers.

Opportunity:

Advancements in Anesthesia Technology

Advancements in anesthesia technology are driving significant growth in the market, enhancing patient safety, precision, and efficiency in surgeries. Innovations such as automated anesthesia delivery, real-time monitoring, and low-flow techniques optimize Sevoflurane usage, reducing wastage and side effects. The rise of minimally invasive procedures and improved vaporizers further boost demand. Additionally, enhanced pharmacokinetics and better recovery profiles make Sevoflurane the preferred choice for anesthetists. These advancements collectively fuel market expansion, ensuring safer and more effective anesthesia administration worldwide.

Threat:

Potential Adverse Effects

The Sevoflurane market faces potential adverse effects due to regulatory restrictions, supply chain disruptions, and health concerns. Stringent environmental regulations on volatile anesthetics hinder market expansion. Supply chain volatility, including shortages of raw materials, affects production and pricing. Additionally, concerns over neurotoxicity in pediatric and elderly patients raise safety issues, leading to reduced adoption. Rising competition from alternative anesthetics and increasing preference for total intravenous anesthesia (TIVA) further restrict market growth and profitability.

Covid-19 Impact:

The COVID-19 pandemic had a mixed impact on the sevoflurane market. While elective surgeries declined due to lockdowns, the demand for Sevoflurane surged in critical care settings, particularly for ventilated COVID-19 patients. Supply chain disruptions and hospital resource reallocation initially slowed market growth, but post-pandemic recovery, increased surgical procedures, and improved healthcare infrastructure have driven a strong resurgence in demand across the industry.

The hospitals segment is expected to be the largest during the forecast period

The hospitals segment is expected to account for the largest market share during the forecast period as these facilities are primary users of the anesthetic for surgical procedures. With rising surgical volumes, increasing healthcare infrastructure, and advancements in anesthesia techniques, hospitals are boosting demand for Sevoflurane. Additionally, the growing prevalence of chronic diseases requiring surgical interventions further fuels market growth. The segment benefits from strong adoption due to its effectiveness, safety profile, and widespread use in general anesthesia, reinforcing its positive impact on market expansion.

The high purity sevoflurane segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the high purity sevoflurane segment is predicted to witness the highest growth rate due to its superior efficacy, safety, and reduced side effects in anesthesia applications. With increasing surgical procedures and rising demand for minimally invasive treatments, hospitals and clinics are prioritizing high-purity formulations for better patient outcomes. Additionally, stringent regulatory standards and advancements in pharmaceutical manufacturing are ensuring consistent quality, further boosting market adoption.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share due to an increase in surgical operations, technological developments in anesthetic, and growing healthcare expenditures. Sevoflurane is the recommended option for inhalation anesthetic because to its effectiveness, quick recovery period, and few side effects. Demand is also fueled by an aging population and the rising incidence of chronic diseases. Its popularity is further aided by continuous research and development in anesthetic administration technologies. This market expansion adds to the region's cutting-edge healthcare infrastructure and guarantees better patient results.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR because of an increase in surgical operations, a growing healthcare infrastructure, and technological breakthroughs in anesthetic. By offering safer and more effective inhalation anesthetic, the market is improving patient outcomes. Demand is further fueled by an aging population, growing medical tourism, and hospital development. Sevoflurane is a major factor in raising surgical effectiveness and general healthcare standards in the area, and government programs to improve healthcare accessibility also support market growth.

Key players in the market

Some of the key players in Sevoflurane Market include AbbVie Inc., Accord Healthcare, AstraZeneca, Baxter International Inc., Beijing Zizhu Pharmaceutical Co., Ltd., Endo International plc, Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Hospira Inc., Jiangsu Hengrui Pharmaceuticals Co., Ltd., Lunan Pharmaceutical Group Co., Ltd., Maruishi Pharmaceutical Co., Ltd., Merck KGaA, Piramal Critical Care, Shandong Keyuan Pharmaceutical Co., Ltd., Shanghai Huayuan Ethylene Co., Ltd. and Troikaa Pharmaceuticals Ltd.

Key Developments:

In March 2025, AstraZeneca and Alteogen Inc. have entered into an exclusive license agreement for ALT-B4, a novel hyaluronidase utilising Hybrozyme(TM) platform technology. Under the terms of the agreement, AstraZeneca will acquire worldwide rights to use ALT-B4 to develop and commercialise subcutaneous formulations of several oncology assets.

In February 2024, AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs). The acquisition marks a major step forward in AstraZeneca delivering on its ambition to transform cancer treatment and outcomes for patients by replacing traditional regimens like chemotherapy and radiotherapy with more targeted treatments.

Products Covered:

  • Generic Sevoflurane
  • Branded Sevoflurane

Formulations Covered:

  • Standard Purity Sevoflurane
  • High Purity Sevoflurane

Distribution Channels Covered:

  • Direct Sales
  • Distributors/Wholesalers
  • Online Pharmacies
  • Retail Pharmacies

Applications Covered:

  • Induction of Anesthesia
  • Maintenance of Anesthesia

End Users Covered:

  • Hospitals
  • Ambulatory Surgical Centers (ASCs)
  • Specialty Clinics
  • Other Healthcare Facilities

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Sevoflurane Market, By Product

  • 5.1 Introduction
  • 5.2 Generic Sevoflurane
  • 5.3 Branded Sevoflurane

6 Global Sevoflurane Market, By Formulation

  • 6.1 Introduction
  • 6.2 Standard Purity Sevoflurane
  • 6.3 High Purity Sevoflurane

7 Global Sevoflurane Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Direct Sales
  • 7.3 Distributors/Wholesalers
  • 7.4 Online Pharmacies
  • 7.5 Retail Pharmacies

8 Global Sevoflurane Market, By Application

  • 8.1 Introduction
  • 8.2 Induction of Anesthesia
  • 8.3 Maintenance of Anesthesia

9 Global Sevoflurane Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals
  • 9.3 Ambulatory Surgical Centers (ASCs)
  • 9.4 Specialty Clinics
  • 9.5 Other Healthcare Facilities

10 Global Sevoflurane Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 AbbVie Inc.
  • 12.2 Accord Healthcare
  • 12.3 AstraZeneca
  • 12.4 Baxter International Inc.
  • 12.5 Beijing Zizhu Pharmaceutical Co., Ltd.
  • 12.6 Endo International plc
  • 12.7 Fresenius Kabi AG
  • 12.8 Hikma Pharmaceuticals PLC
  • 12.9 Hospira Inc.
  • 12.10 Jiangsu Hengrui Pharmaceuticals Co., Ltd.
  • 12.11 Lunan Pharmaceutical Group Co., Ltd.
  • 12.12 Maruishi Pharmaceutical Co., Ltd.
  • 12.13 Merck KGaA
  • 12.14 Piramal Critical Care
  • 12.15 Shandong Keyuan Pharmaceutical Co., Ltd.
  • 12.16 Shanghai Huayuan Ethylene Co., Ltd.
  • 12.17 Troikaa Pharmaceuticals Ltd. .

List of Tables

  • Table 1 Global Sevoflurane Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Sevoflurane Market Outlook, By Product (2024-2032) ($MN)
  • Table 3 Global Sevoflurane Market Outlook, By Generic Sevoflurane (2024-2032) ($MN)
  • Table 4 Global Sevoflurane Market Outlook, By Branded Sevoflurane (2024-2032) ($MN)
  • Table 5 Global Sevoflurane Market Outlook, By Formulation (2024-2032) ($MN)
  • Table 6 Global Sevoflurane Market Outlook, By Standard Purity Sevoflurane (2024-2032) ($MN)
  • Table 7 Global Sevoflurane Market Outlook, By High Purity Sevoflurane (2024-2032) ($MN)
  • Table 8 Global Sevoflurane Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 9 Global Sevoflurane Market Outlook, By Direct Sales (2024-2032) ($MN)
  • Table 10 Global Sevoflurane Market Outlook, By Distributors/Wholesalers (2024-2032) ($MN)
  • Table 11 Global Sevoflurane Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 12 Global Sevoflurane Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 13 Global Sevoflurane Market Outlook, By Application (2024-2032) ($MN)
  • Table 14 Global Sevoflurane Market Outlook, By Induction of Anesthesia (2024-2032) ($MN)
  • Table 15 Global Sevoflurane Market Outlook, By Maintenance of Anesthesia (2024-2032) ($MN)
  • Table 16 Global Sevoflurane Market Outlook, By End User (2024-2032) ($MN)
  • Table 17 Global Sevoflurane Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 18 Global Sevoflurane Market Outlook, By Ambulatory Surgical Centers (ASCs) (2024-2032) ($MN)
  • Table 19 Global Sevoflurane Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 20 Global Sevoflurane Market Outlook, By Other Healthcare Facilities (2024-2032) ($MN)
  • Table 21 North America Sevoflurane Market Outlook, By Country (2024-2032) ($MN)
  • Table 22 North America Sevoflurane Market Outlook, By Product (2024-2032) ($MN)
  • Table 23 North America Sevoflurane Market Outlook, By Generic Sevoflurane (2024-2032) ($MN)
  • Table 24 North America Sevoflurane Market Outlook, By Branded Sevoflurane (2024-2032) ($MN)
  • Table 25 North America Sevoflurane Market Outlook, By Formulation (2024-2032) ($MN)
  • Table 26 North America Sevoflurane Market Outlook, By Standard Purity Sevoflurane (2024-2032) ($MN)
  • Table 27 North America Sevoflurane Market Outlook, By High Purity Sevoflurane (2024-2032) ($MN)
  • Table 28 North America Sevoflurane Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 29 North America Sevoflurane Market Outlook, By Direct Sales (2024-2032) ($MN)
  • Table 30 North America Sevoflurane Market Outlook, By Distributors/Wholesalers (2024-2032) ($MN)
  • Table 31 North America Sevoflurane Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 32 North America Sevoflurane Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 33 North America Sevoflurane Market Outlook, By Application (2024-2032) ($MN)
  • Table 34 North America Sevoflurane Market Outlook, By Induction of Anesthesia (2024-2032) ($MN)
  • Table 35 North America Sevoflurane Market Outlook, By Maintenance of Anesthesia (2024-2032) ($MN)
  • Table 36 North America Sevoflurane Market Outlook, By End User (2024-2032) ($MN)
  • Table 37 North America Sevoflurane Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 38 North America Sevoflurane Market Outlook, By Ambulatory Surgical Centers (ASCs) (2024-2032) ($MN)
  • Table 39 North America Sevoflurane Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 40 North America Sevoflurane Market Outlook, By Other Healthcare Facilities (2024-2032) ($MN)
  • Table 41 Europe Sevoflurane Market Outlook, By Country (2024-2032) ($MN)
  • Table 42 Europe Sevoflurane Market Outlook, By Product (2024-2032) ($MN)
  • Table 43 Europe Sevoflurane Market Outlook, By Generic Sevoflurane (2024-2032) ($MN)
  • Table 44 Europe Sevoflurane Market Outlook, By Branded Sevoflurane (2024-2032) ($MN)
  • Table 45 Europe Sevoflurane Market Outlook, By Formulation (2024-2032) ($MN)
  • Table 46 Europe Sevoflurane Market Outlook, By Standard Purity Sevoflurane (2024-2032) ($MN)
  • Table 47 Europe Sevoflurane Market Outlook, By High Purity Sevoflurane (2024-2032) ($MN)
  • Table 48 Europe Sevoflurane Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 49 Europe Sevoflurane Market Outlook, By Direct Sales (2024-2032) ($MN)
  • Table 50 Europe Sevoflurane Market Outlook, By Distributors/Wholesalers (2024-2032) ($MN)
  • Table 51 Europe Sevoflurane Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 52 Europe Sevoflurane Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 53 Europe Sevoflurane Market Outlook, By Application (2024-2032) ($MN)
  • Table 54 Europe Sevoflurane Market Outlook, By Induction of Anesthesia (2024-2032) ($MN)
  • Table 55 Europe Sevoflurane Market Outlook, By Maintenance of Anesthesia (2024-2032) ($MN)
  • Table 56 Europe Sevoflurane Market Outlook, By End User (2024-2032) ($MN)
  • Table 57 Europe Sevoflurane Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 58 Europe Sevoflurane Market Outlook, By Ambulatory Surgical Centers (ASCs) (2024-2032) ($MN)
  • Table 59 Europe Sevoflurane Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 60 Europe Sevoflurane Market Outlook, By Other Healthcare Facilities (2024-2032) ($MN)
  • Table 61 Asia Pacific Sevoflurane Market Outlook, By Country (2024-2032) ($MN)
  • Table 62 Asia Pacific Sevoflurane Market Outlook, By Product (2024-2032) ($MN)
  • Table 63 Asia Pacific Sevoflurane Market Outlook, By Generic Sevoflurane (2024-2032) ($MN)
  • Table 64 Asia Pacific Sevoflurane Market Outlook, By Branded Sevoflurane (2024-2032) ($MN)
  • Table 65 Asia Pacific Sevoflurane Market Outlook, By Formulation (2024-2032) ($MN)
  • Table 66 Asia Pacific Sevoflurane Market Outlook, By Standard Purity Sevoflurane (2024-2032) ($MN)
  • Table 67 Asia Pacific Sevoflurane Market Outlook, By High Purity Sevoflurane (2024-2032) ($MN)
  • Table 68 Asia Pacific Sevoflurane Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 69 Asia Pacific Sevoflurane Market Outlook, By Direct Sales (2024-2032) ($MN)
  • Table 70 Asia Pacific Sevoflurane Market Outlook, By Distributors/Wholesalers (2024-2032) ($MN)
  • Table 71 Asia Pacific Sevoflurane Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 72 Asia Pacific Sevoflurane Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 73 Asia Pacific Sevoflurane Market Outlook, By Application (2024-2032) ($MN)
  • Table 74 Asia Pacific Sevoflurane Market Outlook, By Induction of Anesthesia (2024-2032) ($MN)
  • Table 75 Asia Pacific Sevoflurane Market Outlook, By Maintenance of Anesthesia (2024-2032) ($MN)
  • Table 76 Asia Pacific Sevoflurane Market Outlook, By End User (2024-2032) ($MN)
  • Table 77 Asia Pacific Sevoflurane Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 78 Asia Pacific Sevoflurane Market Outlook, By Ambulatory Surgical Centers (ASCs) (2024-2032) ($MN)
  • Table 79 Asia Pacific Sevoflurane Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 80 Asia Pacific Sevoflurane Market Outlook, By Other Healthcare Facilities (2024-2032) ($MN)
  • Table 81 South America Sevoflurane Market Outlook, By Country (2024-2032) ($MN)
  • Table 82 South America Sevoflurane Market Outlook, By Product (2024-2032) ($MN)
  • Table 83 South America Sevoflurane Market Outlook, By Generic Sevoflurane (2024-2032) ($MN)
  • Table 84 South America Sevoflurane Market Outlook, By Branded Sevoflurane (2024-2032) ($MN)
  • Table 85 South America Sevoflurane Market Outlook, By Formulation (2024-2032) ($MN)
  • Table 86 South America Sevoflurane Market Outlook, By Standard Purity Sevoflurane (2024-2032) ($MN)
  • Table 87 South America Sevoflurane Market Outlook, By High Purity Sevoflurane (2024-2032) ($MN)
  • Table 88 South America Sevoflurane Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 89 South America Sevoflurane Market Outlook, By Direct Sales (2024-2032) ($MN)
  • Table 90 South America Sevoflurane Market Outlook, By Distributors/Wholesalers (2024-2032) ($MN)
  • Table 91 South America Sevoflurane Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 92 South America Sevoflurane Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 93 South America Sevoflurane Market Outlook, By Application (2024-2032) ($MN)
  • Table 94 South America Sevoflurane Market Outlook, By Induction of Anesthesia (2024-2032) ($MN)
  • Table 95 South America Sevoflurane Market Outlook, By Maintenance of Anesthesia (2024-2032) ($MN)
  • Table 96 South America Sevoflurane Market Outlook, By End User (2024-2032) ($MN)
  • Table 97 South America Sevoflurane Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 98 South America Sevoflurane Market Outlook, By Ambulatory Surgical Centers (ASCs) (2024-2032) ($MN)
  • Table 99 South America Sevoflurane Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 100 South America Sevoflurane Market Outlook, By Other Healthcare Facilities (2024-2032) ($MN)
  • Table 101 Middle East & Africa Sevoflurane Market Outlook, By Country (2024-2032) ($MN)
  • Table 102 Middle East & Africa Sevoflurane Market Outlook, By Product (2024-2032) ($MN)
  • Table 103 Middle East & Africa Sevoflurane Market Outlook, By Generic Sevoflurane (2024-2032) ($MN)
  • Table 104 Middle East & Africa Sevoflurane Market Outlook, By Branded Sevoflurane (2024-2032) ($MN)
  • Table 105 Middle East & Africa Sevoflurane Market Outlook, By Formulation (2024-2032) ($MN)
  • Table 106 Middle East & Africa Sevoflurane Market Outlook, By Standard Purity Sevoflurane (2024-2032) ($MN)
  • Table 107 Middle East & Africa Sevoflurane Market Outlook, By High Purity Sevoflurane (2024-2032) ($MN)
  • Table 108 Middle East & Africa Sevoflurane Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 109 Middle East & Africa Sevoflurane Market Outlook, By Direct Sales (2024-2032) ($MN)
  • Table 110 Middle East & Africa Sevoflurane Market Outlook, By Distributors/Wholesalers (2024-2032) ($MN)
  • Table 111 Middle East & Africa Sevoflurane Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 112 Middle East & Africa Sevoflurane Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 113 Middle East & Africa Sevoflurane Market Outlook, By Application (2024-2032) ($MN)
  • Table 114 Middle East & Africa Sevoflurane Market Outlook, By Induction of Anesthesia (2024-2032) ($MN)
  • Table 115 Middle East & Africa Sevoflurane Market Outlook, By Maintenance of Anesthesia (2024-2032) ($MN)
  • Table 116 Middle East & Africa Sevoflurane Market Outlook, By End User (2024-2032) ($MN)
  • Table 117 Middle East & Africa Sevoflurane Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 118 Middle East & Africa Sevoflurane Market Outlook, By Ambulatory Surgical Centers (ASCs) (2024-2032) ($MN)
  • Table 119 Middle East & Africa Sevoflurane Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 120 Middle East & Africa Sevoflurane Market Outlook, By Other Healthcare Facilities (2024-2032) ($MN)